Antidiuretic Hormone Antagonist to Reduce Cystine Stone Formation
Authors: Hans de Boer, Anita Roelofsen, Pim M.W. Janssens
Journal: Annals of Internal Medicine (2012)

Letters18 September 2012Antidiuretic Hormone Antagonist to Reduce Cystine Stone FormationHans de Boer, MD, PhD, Anita Roelofsen, MD, and Pim M.W. Janssens, PhDHans de Boer, MD, PhDFrom Rijnstate Hospital, 6881 NR Arnhem, the Netherlands., Anita Roelofsen, MDFrom Rijnstate Hospital, 6881 NR Arnhem, the Netherlands., and Pim M.W. Janssens, PhDFrom Rijnstate Hospital, 6881 NR Arnhem, the Netherlands.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-6-201209180-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Cystinuria is the most common inherited cause of recurrent kidney stones (1). Its principal disorder is impaired reabsorption of cystine in the proximal renal tubule. As a result, large amounts of cystine are excreted in urine, kidney stones form because cystine is poorly soluble, and the patient experiences many urologic interventions. Measures to prevent stone formation include changing the diet to reduce cystine excretion, diluting urine to a lower cystine concentration, and making the urine alkaline to improve cystine solubility. Cystine-binding thiol drugs also improve cystine solubility but need to be discontinued because of adverse effects in 30% to ...References1. Mattoo A, Goldfarb DS. Cystinuria. Semin Nephrol. 2008;28:181-91. [PMID: 18359399] CrossrefMedlineGoogle Scholar2. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371:1624-32. [PMID: 18468546] CrossrefMedlineGoogle Scholar3. Doggrell SA. Tolvaptan (Otsuka). Curr Opin Investig Drugs. 2004;5:977-83. [PMID: 15503654] MedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Hans de Boer, MD, PhD; Anita Roelofsen, MD; Pim M.W. Janssens, PhDAffiliations: From Rijnstate Hospital, 6881 NR Arnhem, the Netherlands.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCystinuria: an update on pathophysiology, genetics, and clinical managementTolvaptan treatment of cystine urolithiasis in a mouse model of cystinuriaPharmacological Dilutional Therapy Using the Vasopressin Antagonist Tolvaptan for Young Patients With Cystinuria: A Pilot InvestigationThe effect of additional drug therapy as metaphylaxis in patients with cystinuria: a systematic reviewUpdate on cystine stones: current and future concepts in treatmentEstablished and recent developments in the pharmacological management of urolithiasis: an overview of the current treatment armamentariumCystine StonesShort-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid SupersaturationsTolvaptan might prevent kidney stone formationRenal CalculiCopeptin Is Associated with Kidney Length, Renal Function, and Prevalence of Simple Cysts in a Population-Based StudyUpdate on cystinuria 18 September 2012Volume 157, Issue 6Page: 459-460KeywordsAntidiuretic hormoneAttentionDietDrugsExcretionGlomerular filtration rateKidney stonesRashesUrinationUrine ePublished: 18 September 2012 Issue Published: 18 September 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...